Business Context and Reporting Period
This Form 8-K is a current report filed by AIT Therapeutics, Inc. (not Beyond Air, Inc.) on February 22, 2018, covering events that occurred on February 16, 2018. The company is an emerging growth company focused on developing nitric oxide (NO) delivery systems for respiratory conditions.
Key Financial Metrics
The filing details a capital raise event rather than periodic financial performance metrics.
- Gross Proceeds: Approximately $9.82 million raised from the sale of warrants and the immediate exercise of Tranche A Warrants.
- Securities Issued: Warrants to purchase an aggregate of 4,599,604 shares of common stock.
- Warrant Structure:
- 2,299,802 Tranche A Warrants (exercised immediately at $4.25/share).
- 2,299,802 Tranche B Warrants (exercisable within three years at $4.25/share).
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific values for these standard financial metrics.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement and a Registration Rights Agreement on February 16, 2018. This transaction resulted in an immediate increase in cash resources of approximately $9.82 million and an increase in the potential share count upon full exercise of the warrants.
Guidance, Outlook, and Risks
Regulatory and Clinical Outlook
- Persistent Pulmonary Hypertension of the Newborn (PPHN): Plans to submit a 510(k) premarket notification to the FDA in Q4 2018; international filings expected in 2019.
- Bronchiolitis: Expects to initiate a Phase 3 pivotal trial in Q4 2018, complete it in Q2 2019, and submit a 510(k) to the FDA before the end of 2019.
- Nontuberculous Mycobacteria (NTM) Abscessus: A compassionate use treatment is ongoing at the NIH (expected completion Q1 2018). The company anticipates meeting with the FDA in Q2 2018 to discuss pivotal trial design.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks include the unproven nature of the drug discovery approach, dependence on third parties for development and manufacturing, difficulty in patient enrollment, and the early-stage status of all product candidates. Actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the exact number of shares issued upon the immediate exercise of Tranche A Warrants versus the total warrant count.
- Confirm the dilution impact of the 4,599,604 warrant shares on existing shareholders.
- Monitor the timeline for the 510(k) submission for PPHN and the Phase 3 trial initiation for bronchiolitis as stated in Q4 2018.
- Review the Registration Rights Agreement (Exhibit 10.2) for specific lock-up periods or resale restrictions.
- Check subsequent filings for the outcome of the FDA meeting regarding NTM abscessus trial design scheduled for Q2 2018.